Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis
Aim: Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3’s ability in assessing prognosis of HF patients. Method: We searched MEDLINE and Embase up to November 2014. Test performance characteristic...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
9 February 2016
|
| In: |
Biomarkers in medicine
Year: 2016, Volume: 10, Issue: 3, Pages: 329-342 |
| ISSN: | 1752-0371 |
| DOI: | 10.2217/bmm.15.121 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2217/bmm.15.121 Verlag, lizenzpflichtig, Volltext: https://www.futuremedicine.com/doi/10.2217/bmm.15.121 
|
| Author Notes: | Yueh-Sheng Chen, Weng-Tein Gi, Tin-Yun Liao, Meng-Tse Gabriel Lee, Si-Huei Lee, Wan-Ting Hsu, Shy-Shin Chang and Chien-Chang Lee |
| Summary: | Aim: Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3’s ability in assessing prognosis of HF patients. Method: We searched MEDLINE and Embase up to November 2014. Test performance characteristics were summarized using forest plots and hierarchical summary receiver operating characteristic curves. Results: The diagnostic odds ratio of Gal-3 in predicting mortality in chronic HF patients was 2.36 (95% CI: 1.71-3.26) and 2.30 (95% CI: 1.76-3.01) in acute HF patients. Conclusion: Elevated levels of Gal-3 are associated with mortality in both acute and chronic HF patients. However, current evidence does not support sole use of Gal-3 for prognosis evaluation of HF patients. |
|---|---|
| Item Description: | Gesehen am 30.04.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1752-0371 |
| DOI: | 10.2217/bmm.15.121 |